Palisade Bio, Inc. PALI
1.13 USD -0.06 (-5.04%)
At closeNov 10, 2026, 4:00 PM EST
1.14 +0.01 +1.16%
After hours · Nov 10, 4:00 PM ET
1.11 Day range 1.20
1.08 52-week range 2.86
- YTD
- -51.91%
- 1 year
- -36.16%
News
benzinga.com Palisade Bio Q3 EPS $(0.07) Misses $(0.06) Estimate Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 81.58 percent increase over losses of…
globenewswire.com Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027 New…
benzinga.com Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027 PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability29 of…
benzinga.com Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The…- benzinga.com HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
benzinga.com Palisade Bio Highlights PALI-2108 Clinical And Translational Findings In 5 ACG 2026 Presentations Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 developmentTwo…